Welcome to our dedicated page for Immuron SEC filings (Ticker: IMRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immuron Limited’s SEC filings document its foreign private issuer disclosures and ASX announcements furnished on Form 6-K. The filings include half-year financial reports, strategic updates and investor presentations describing the company’s oral polyclonal antibody platform, Hyper-Immune products, Travelan®, ProIBS®, and clinical programs for gastrointestinal infectious diseases.
The filing record also covers shareholder meeting results, small-holding share sale facility disclosures, R&D Tax Incentive notices, regional sales updates, and governance authorizations by the board. These documents provide formal disclosures on operating results, research and development funding, ordinary-share matters, and public-company reporting obligations for IMRN’s ASX and Nasdaq-traded securities.
Immuron Limited submitted a Form 6-K as a foreign private issuer for November 2025. The company is furnishing to U.S. investors copies of two announcements it filed with the Australian Securities Exchange on November 7, 2025: an application for quotation of securities and a cleansing notice.
These Australian announcements are attached to the Form 6-K as exhibits 99.1 and 99.2. The company notes that this Form 6-K, including the exhibits, is being furnished rather than filed and will only be incorporated into other U.S. securities filings if specifically referenced.
Immuron Limited furnished a Form 6-K announcing that it has attached an Australian Securities Exchange notice titled “Proposed issue of securities - IMC.” The filing provides the ASX public notice as Exhibit 99.1 for U.S. investors’ awareness.
The submission is an information update and does not include financial results or transaction terms. It primarily serves to make the ASX announcement available to the U.S. market.
Immuron Limited (IMRN) furnished a Form 6-K announcing it has attached an Australian Securities Exchange notice as Exhibit 99.1. The exhibit is titled “IMM-529 IND approved by FDA”, indicating the company reported an FDA approval of an Investigational New Drug for IMM-529. The ASX announcement was published on November 5, 2025.
The report states it is being furnished, not filed, under the Exchange Act and will not be incorporated by reference into other filings except where expressly referenced.
Immuron Limited submitted a Form 6-K as a foreign private issuer to provide U.S. investors with access to an announcement it released on the Australian Securities Exchange. The filing states that the company published a public notice on October 31, 2025 titled “Clinical Trial Update”, and that this announcement is attached to the Form 6-K as Exhibit 99.1. The company also clarifies that this Form 6-K, including the exhibit, is being furnished rather than filed under U.S. securities laws and will not be incorporated into other Securities Act filings unless specifically referenced.
Immuron Limited submitted a Form 6-K as a foreign private issuer, forwarding to U.S. investors an announcement previously released on the Australian Securities Exchange. The attached exhibit is a “Notification of cessation of securities”, indicating that certain securities have ceased, though specific details are only contained in the exhibit.
Immuron Limited submitted a Form 6-K to provide U.S. investors with an announcement it released on the Australian Securities Exchange. The attached notice is titled “Immuron launch PROIBS for IBS,” indicating the company has announced the launch of a product called PROIBS aimed at irritable bowel syndrome (IBS). The Form 6-K simply furnishes this ASX announcement as an exhibit and states that it is not deemed filed under the Exchange Act nor automatically incorporated by reference into other U.S. securities filings.
Immuron Limited furnished a Form 6-K as a foreign private issuer for October 2025. The company attached as Exhibit 99.1 an Emerging Growth Conference Presentation that had been announced on the Australian Securities Exchange on October 23, 2025.
The company notes that this Form 6-K, including its exhibit, is furnished rather than filed under U.S. securities laws and will not be incorporated into other U.S. securities filings unless specifically referenced.
Immuron Limited furnished a Form 6-K to provide investors with an Australian Securities Exchange announcement dated October 21, 2025. The filing attaches Exhibit 99.1 titled “Presentation to AusBiotech Invest 2025 Conference.”
The material is furnished, not filed, under the Exchange Act and is not incorporated by reference into other securities filings unless specifically referenced. This update primarily shares the presentation made available to the market.
Immuron Limited furnished a Form 6‑K that attaches two Australian Securities Exchange announcements. The notices, dated October 20, 2025, are titled “Application for quotation of securities - IMC” and “Cleansing Notice.”
The company states this Form 6‑K, including the exhibits, is being furnished and is not deemed “filed” under the Exchange Act, and it is not incorporated by reference into other filings unless expressly referenced.